Free Trial

Sera Prognostics (SERA) Competitors

Sera Prognostics logo
$2.72 +0.30 (+12.40%)
Closing price 04:00 PM Eastern
Extended Trading
$2.72 +0.00 (+0.18%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SERA vs. AIRS, VMD, TOI, DCGO, XGN, EUDA, QIPT, NAKA, KDLY, and ATPC

Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include AirSculpt Technologies (AIRS), Viemed Healthcare (VMD), Oncology Institute (TOI), DocGo (DCGO), Exagen (XGN), EUDA Health (EUDA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry.

Sera Prognostics vs. Its Competitors

Sera Prognostics (NASDAQ:SERA) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

AirSculpt Technologies has higher revenue and earnings than Sera Prognostics. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sera Prognostics$80K1,280.78-$32.90M-$0.94-2.89
AirSculpt Technologies$180.35M1.75-$8.25M-$0.30-17.90

In the previous week, Sera Prognostics and Sera Prognostics both had 1 articles in the media. AirSculpt Technologies' average media sentiment score of 1.02 beat Sera Prognostics' score of 0.00 indicating that AirSculpt Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Sera Prognostics Neutral
AirSculpt Technologies Positive

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Comparatively, 76.6% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sera Prognostics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, AirSculpt Technologies has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.

AirSculpt Technologies has a consensus target price of $3.75, indicating a potential downside of 30.17%. Given AirSculpt Technologies' stronger consensus rating and higher possible upside, analysts plainly believe AirSculpt Technologies is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
AirSculpt Technologies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

AirSculpt Technologies has a net margin of -9.95% compared to Sera Prognostics' net margin of -28,685.22%. AirSculpt Technologies' return on equity of -15.01% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sera Prognostics-28,685.22% -51.35% -37.21%
AirSculpt Technologies -9.95%-15.01%-5.85%

Summary

AirSculpt Technologies beats Sera Prognostics on 12 of the 14 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SERA vs. The Competition

MetricSera PrognosticsMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$91.17M$7.24B$5.47B$8.95B
Dividend YieldN/A2.83%5.25%4.06%
P/E Ratio-2.8918.6719.7120.50
Price / Sales1,280.7834.17435.75120.29
Price / CashN/A23.6936.8257.86
Price / Book1.946.727.985.56
Net Income-$32.90M$230.16M$3.16B$248.40M
7 Day Performance5.02%1.27%3.69%6.04%
1 Month Performance75.48%2.35%2.91%7.69%
1 Year Performance-49.44%46.16%34.30%20.97%

Sera Prognostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SERA
Sera Prognostics
0.6202 of 5 stars
$2.72
+12.4%
N/A-55.1%$91.17M$80K-2.89120High Trading Volume
AIRS
AirSculpt Technologies
0.6521 of 5 stars
$5.39
-0.2%
$3.75
-30.4%
+37.2%$317.41M$180.35M-17.97240Positive News
VMD
Viemed Healthcare
1.3168 of 5 stars
$6.87
-3.9%
N/A+7.3%$282.60M$224.26M22.901,179
TOI
Oncology Institute
1.3717 of 5 stars
$2.56
+1.6%
$7.00
+173.4%
+403.4%$224.87M$403.15M-3.66660
DCGO
DocGo
2.3077 of 5 stars
$1.52
-3.8%
$3.56
+134.2%
-47.9%$161.13M$520.50M-76.004,407
XGN
Exagen
2.9705 of 5 stars
$6.96
-1.3%
$7.50
+7.8%
+300.0%$150.16M$55.64M-8.29220
EUDA
EUDA Health
N/A$3.33
-1.5%
N/A-11.4%$125.59M$4.01M0.002
QIPT
Quipt Home Medical
2.9118 of 5 stars
$1.73
-2.8%
$2.85
+64.7%
-42.3%$77.33M$245.91M-8.241,200News Coverage
NAKA
KindlyMD
N/A$12.04
-5.6%
N/AN/A$76.88M$2.47M-15.64N/A
KDLY
Kindly MD
N/A$12.75
-2.8%
N/A+466.7%$76.78M$2.47M-16.56N/A
ATPC
Agape ATP
N/A$1.40
+2.6%
N/A-65.2%$68.01M$1.29M-2.3240

Related Companies and Tools


This page (NASDAQ:SERA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners